News and Announcements
DMX-200 Phase 2a trial meets primary end point for Chronic Kidney Disease
- Published July 17, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
DMX-200 is an adjunct therapy in which patients who are already on the standard of care angiotensin II type I receptor blocker (irbesartan) are also dosed with a chemokine receptor CCR2 blocker (propagermanium).
This Phase 2a trial was a dose escalation study in 27 patients with chronic kidney disease of a variety of causes. The primary end point was safety, with changes in biomarkers such as excess protein in the urine (proteinuria) as secondary end points. Proteinuria is a common symptom of kidney disease and is prognostic of deterioration of kidney function. High levels of protein in the urine also exacerbate the inflammation component of kidney disease, setting up a vicious cycle of disease progression.
The data released on the 12th of July from the DMX-200 Phase 2a trial was that DMX-200 has demonstrated safety and tolerability in this diverse patient population, and that in some patient groups the clinically meaningful result of 50% reduction in proteinuria was seen. This reduction was over and above the best response the patients had achieved on the standard of care therapy. These data provide the company with a wealth of information to design a more targeted Phase 2b efficacy study, and deepen engagement with potential licensing partners.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
